A reasonable person might pause in the middle of reading a skin cream’s ingredient list and its claims of “cellular renewal” and “collagen restoration,” wondering what any of this really means. Not in a philosophical sense. legally.
Most consumers are unaware of the complexity of the answer, which is also much more lucrative for those who sell the goods.
Theoretically, intent determines the regulatory boundary between a drug and a cosmetic in the US. A cosmetic is a moisturizer that hydrates the skin to reduce the appearance of wrinkles. Federal law defines a product as a drug if it purports to actually rebuild collagen or change the structure of the skin. The FDA must approve medications before they can be sold, so this distinction is important. Cosmetics don’t. A large amount of money secretly resides in the space between those two categories.
Brands are now incredibly proficient in language. You’ll notice the careful wording in any mid-range pharmacy, such as “visibly reduces,” “appears firmer,” and “helps skin look younger.” It looks like that hedge word is doing actual legal work. It keeps a product on the line of cosmetics. If you go one step further and say that a cream restructures aging tissue or stimulates collagen, you’ve entered the realm of drugs, which theoretically need clinical proof and federal approval. In reality, a lot of brands cross that boundary without facing any repercussions. Yes, the FDA has sent out warning letters. However, given the size of the industry, enforcement has remained lax.
Perhaps this was never totally coincidental. Supplement manufacturers were able to sell their products with virtually no pre-market regulatory burden thanks to the 1994 Dietary Supplements Health and Education Act, provided they refrained from making explicit disease claims. On the other side of that door, the anti-aging industry established a vast commercial ecosystem. Products that promise to slow aging at the cellular level, such as hormone precursors, amino acid blends, and herbal compounds, are marketed in ways that would necessitate clinical trials if a pharmaceutical company made the same claims.
Perhaps the most striking example is found in the human growth hormone sector of this world. Distributing HGH for anti-aging purposes is expressly forbidden by federal law. However, clinics advertise age-management programs openly, frequently in affluent zip codes, to patients who are concerned about aging and prepared to make the necessary financial investments. There is a clear discrepancy between what the law states and what takes place in some of these clinics. Due in large part to the lack of resources available to enforcement agencies, this gap continues to exist.
Observing all of this from a distance gives me the impression that the industry has accurately calculated something about institutional bandwidth and human psychology. People have an urgent, visceral need for solutions to aging. Regulators are overworked and underfunded. Additionally, the industry has enough leeway to function in ambiguity thanks to the legal framework’s intent-based distinctions and 30-year-old supplement exemptions.
There is a cost to that ambiguity. Customers spend actual money—sometimes large sums of money—on goods that have not been shown to be effective. Poorly tested ingredients can have negative health effects on some people. The social cost, which includes a whole cultural discourse about aging that has been influenced, in part, by marketing based on regulatory workarounds, is more difficult to quantify but not invisible.
This does not imply that all anti-aging products are fake. There is real evidence to support some formulations. However, it is more difficult to locate the honest version of this industry than the lucrative one. The gap between the two will probably continue to widen until the legal system catches up with business reality.
